NAPIGEN Completes $7.85 Million Funding Round to Advance Its Mitochondrial and Chloroplast Gene Editing Technology
Funds will be used to develop hybrid seed technology in wheat and rice through gene editing of plant mitochondriaWILMINGTON, Del.,...
Day: July 12, 2022
BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia
SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , Sunnyvale, Calif. – BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics...
Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022
MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
Agile Therapeutics Updates Second Quarter 2022 Guidance
Twirla® Demand Guidance (Total Cycles) Expected to be at Midpoint of Guided Range Operating Expenses (OPEX) Expected to be Below...
Reflect Scientific Inc Second Quarter Shareholder Letter
OREM, Utah, July 12, 2022 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services...
electroCore Provides Select Second Quarter 2022 Financial Guidance
Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021June 30, 2022, cash and cash...
scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure
Study results favor FUROSCIX®versus “treatment as usual” in composite primary endpoint and all secondary endpoints FUROSCIX demonstrated an acceptable tolerability...
New Access Vascular Retrospective Data Review Demonstrates Midline Catheters Composed of Advanced Biomaterials May Improve Dwell Times
Data also finds using materials that mimic the body’s chemistry leads to meaningful reductions in complications such as phlebitis, occlusion,...
IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery...
Alignment Healthcare to Introduce Award-Winning Medicare Advantage Plans with its Unique Care Model to Half a Million Medicare-Eligible Adults in Florida
ORANGE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, will begin offering Alignment...
Recce Pharmaceuticals Appoints Philip Sutton, Ph.D., as Vice President of Translational Sciences
– Dr. Sutton to help advance Recce’s portfolio of infectious disease programs focused on significant unmet medical needs – SYDNEY...
MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs
LG Chem to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its T-cell therapy candidates...
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III
ProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol “PROK” on July 12, 2022ProKidney receives...
Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug
Las Vegas, NV, July 12, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc.,...
Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022
PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that...
Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022
WOBURN, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
Quotient Limited and InfYnity Biomarkers Announce Partnership to Expand MosaiQ Infectious Disease Menu
Partnership aims to expand the Transfusion Transmissible Infections, other Infectious Diseases, and clinical diagnostics assay menu on Quotient’s multimodality, multiplexed...
CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal
MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN...
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022...
Aurora Spine Announces New FDA indication clearance of Lumbar Spinal Stenosis for its ZIP™ series of MIS implants
CARLSBAD, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),...